| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 4.8K | 10.2% | 25.8% |
| Total Income | 4.9K | 9.8% | 26.1% |
| Expenditure | 4.6K | 6.0% | 20.7% |
| PBT | 258.47 | 47.3% | 527.0% |
| Net Profit | 210.64 | 50.2% | 682.8% |
| OPM | 13.77% | 2.79pp | 3.60pp |
| NPM | 4.33% | 3.51pp | 3.63pp |
| EPS | 29.17 | 50.2% | 682.0% |
Detailed report is being prepared.
Margin Normalisation Watch as UFLEX Reports Q2
After a 21-quarter high EBITDA margin of 17% in Q1, UFLEX is expected to show some normalisation in Q2, though growth momentum remains intact with FII accumulation and new capacity coming online.
The Setup
UFLEX delivered an exceptional Q1 FY27—revenue up 37.6% YoY to ₹5,397 Cr, EBITDA margin at a 21-quarter high of 17%, and PAT surging 630% YoY to ₹423 Cr. The market rewarded the print with a 20% rally. Management guided for 35% growth in both revenue and EBITDA for the full year FY27, signalling confidence in execution and new capacity ramp-ups. Q2, however, is where the Street will be watching closely: management itself flagged that Q2 will see some normalisation from Q1's exceptional realisations. The question is where margins settle and whether growth momentum stays on the 35% trajectory.
~30–35% YoY
In line with FY27 guidance; Q1 set the bar at 37.6%
~13–15%
Below Q1's 17% high; normalisation from peak realisations
Egypt line ramp + value mix
New capacities contributing; recovery in key geographies
Leverage on higher base
Q1 base effects ease; normalised finance costs to track
What a Strong vs Weak Print Looks Like
Strong print: Revenue growth north of 32% YoY, EBITDA margin at or above 14%, and commentary that volumes are tracking the guidance case. New capacity utilisation ramping into plan, FX tailwinds stable, and management upgrading the year-end outlook. Stock could re-rate toward the analyst median of ₹752 if execution tightens. Weak print: Revenue growth below 28% YoY or EBITDA margin slipping below 12%. Mix headwinds or price cuts in key segments, delays in Egypt line contribution, or early signs of FY28 demand softening. That could trigger profit-taking after the Q1 rally.
On Track for Full-Year?
After Q1's exceptional print, UFLEX is on track for the 35% growth guidance if Q2–Q4 average mid-20s growth. Q1 alone was 37.6%, so normalisation to 30–35% would still keep the year in the guided range. The wildcard is the Egypt line's contribution and whether the value-added product mix (margins) holds as capacity comes online. If Q2 shows margin slippage below 12%, investors will need clarity on whether this is volume-ramp normality or a sign of pricing pressure, which would challenge the FY27 guide.
Since Last Quarter: The Event Scan
1 · Patent Grant (Sep 18, 2026)
UFLEX granted Patent No. 603158 for a high-speed twin aseptic pack machine for liquid products. Underscores R&D momentum in packaging tech; positive for product differentiation and licensing upside.
2 · ESG Upgrade (Aug 7–19, 2026)
Upgraded to ESG rating of 61/100 (Strong) from earlier 58/100 (Adequate). M&A attractiveness and investor sentiment incrementally helped.
3 · AGM Approvals & MOA Alteration (Jul 29, 2026)
Shareholders approved director re-appointments and MOA alteration at 37th AGM. Director slate re-elected; routine governance—no surprises.
4 · Insider Window Closure (Sep 23, 2026)
Trading window closed from Oct 1, 2026 until 48 hours post-result declaration. Standard pre-result blackout; no material insider activity flagged.
5 · FII Accumulation (Q1 vs Q2 ownership)
FII stake rose 82 bps QoQ to 10.03% (vs 9.21% in Q4 FY26). Steady accumulation signalling foreign fund confidence in the growth narrative.
To Watch on November 12
1 · Margin Normalisation Level
If EBITDA margin stays above 14%, it signals mix/volume holding through the quarter. Below 12% and guidance credibility takes a hit. Watch the breakdown: are price cuts/mix the driver, or is it volume ramp costs?
2 · Egypt & New Capacity Ramp
Management commentary on how much Egypt contributed to Q2 revenue and when it ramps to full utilisation. This is the FY28 visibility engine; delays or lower-than-plan contribution could soften the year-end outlook.
3 · FY27 Guidance Reconfirmation
Will management stick to 35% growth for full year, or pre-empt Q3–Q4 with a slight downside revision if Q2 normalisation is steeper than expected? Guidance clarity will drive post-result sentiment.
UFLEX enters Q2 with a 70% stock rally post-Q1 and 35% FY27 growth on the table—lofty but defended by management, supported by 8 of 9 Buy ratings, and anchored in new capacity coming online. Q2 is the normalisation quarter, and the Street knows it; the task is to ensure normalisation is plan-like, not demand-driven. Revenue staying 30%+ YoY growth and margin holding mid-13% will prove the story is intact. Guidance reaffirmation and Egypt ramp colour will define whether this is a dip-buying opportunity (post a pause) or the start of a longer consolidation.